<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04052451</url>
  </required_header>
  <id_info>
    <org_study_id>MET-2-301</org_study_id>
    <nct_id>NCT04052451</nct_id>
  </id_info>
  <brief_title>The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression and/or Generalized Anxiety Disorder</brief_title>
  <official_title>The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression and/or Generalized Anxiety Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NuBiyota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NuBiyota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will measure the effects of MET-2 on symptoms of depression and anxiety using pre-&#xD;
      and post-treatment scores for overall depression and anxiety and other symptoms of&#xD;
      depression, such as sleep and anhedonia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will measure the effects of MET-2 on symptoms of depression and anxiety using pre-&#xD;
      and post-treatment scores for overall depression and anxiety and other symptoms of&#xD;
      depression, such as sleep and anhedonia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 16, 2019</start_date>
  <completion_date type="Actual">May 1, 2020</completion_date>
  <primary_completion_date type="Actual">May 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is an open label study with one arm for subjects diagnosed with major depression disorder and one arm for subjects diagnosed with generalized anxiety disorder</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Week 10</time_frame>
    <description>The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Generalized Anxiety Disorder - 7 (GAD-7)</measure>
    <time_frame>Week 10</time_frame>
    <description>The GAD-7 is a seven domain, self-reported questionnaire for screening and assessing severity of generalized anxiety disorder.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Depression, Anxiety</condition>
  <arm_group>
    <arm_group_label>Major Depression Disorder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MET-2 will be given to subjects with major depression disorder and its effect on mood will be measured</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Generalized Anxiety Disorder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MET-2 will be given to subjects with generalized anxiety disorder and its effect on mood will be measured</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MET-2</intervention_name>
    <description>Subjects will take study medication once daily for the duration of the study</description>
    <arm_group_label>Generalized Anxiety Disorder</arm_group_label>
    <arm_group_label>Major Depression Disorder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to provide informed consent.&#xD;
&#xD;
          2. Not pregnant&#xD;
&#xD;
          3. Willing to participate in follow up as part of the study&#xD;
&#xD;
          4. Diagnosis of MDD and/or GAD by MINI&#xD;
&#xD;
          5. Current depressive episode with a MADRS score of ≥15 or Current GAD episode with GAD-7&#xD;
             score of ≥8.&#xD;
&#xD;
          6. Able to understand and comply with the requirements of the study&#xD;
&#xD;
          7. Able to provide stool and blood samples.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of chronic diarrhea&#xD;
&#xD;
          2. Need for regular use of agents that affect GI motility (narcotics such as codeine or&#xD;
             morphine, agents such as loperamide or metoclopramide)&#xD;
&#xD;
          3. Colostomy&#xD;
&#xD;
          4. Elective surgery that will require preoperative antibiotics planned within 6 months of&#xD;
             enrolment&#xD;
&#xD;
          5. Pregnant, breastfeeding, or planning to get pregnant in the next 6 months&#xD;
&#xD;
          6. Any condition for which, in the opinion of the investigator, the participant should be&#xD;
             excluded from the study.&#xD;
&#xD;
          7. Current use of any antidepressant/antianxiety drug (eligible to participate after a&#xD;
             4-week washout period)&#xD;
&#xD;
          8. Use of any antibiotic drug in the past 4 weeks (may be eligible to participate after a&#xD;
             1-month washout period)&#xD;
&#xD;
          9. History of alcohol or substance dependence in the past 6 months&#xD;
&#xD;
         10. Daily use of probiotic product in the past 2 weeks (may be eligible to participate&#xD;
             after a 2-week washout period)&#xD;
&#xD;
         11. Use of any type of laxative in the last 2 weeks.&#xD;
&#xD;
         12. Consumption of products fortified in probiotics&#xD;
&#xD;
         13. High suicidal risk, as measured by MADRS item 10 score more than 3 (or 4)&#xD;
&#xD;
         14. Current psychotic symptoms&#xD;
&#xD;
         15. Bipolar Depression&#xD;
&#xD;
         16. History of epilepsy or uncontrolled seizures&#xD;
&#xD;
         17. Immunodeficiency (immuno-compromised and immuno-suppressed participants; e.g. acquired&#xD;
             immune deficiency syndrome [AIDS], lymphoma, participants undergoing long-term&#xD;
             corticosteroid treatment, chemotherapy and allograft participants)&#xD;
&#xD;
         18. Unstable medical conditions or serious diseases/conditions (e.g. cancer,&#xD;
             cardiovascular, renal, lung, diabetes, psychiatric illness, bleeding disorders, etc.)&#xD;
&#xD;
         19. The use of natural health products (Natural health products [NHPs]; e.g. St. John's&#xD;
             Wort, passion flower, etc.) that affect depression&#xD;
&#xD;
         20. History of Electroconvulsive therapy (ECT)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Providence Care Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 8, 2019</study_first_submitted>
  <study_first_submitted_qc>August 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2019</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will not be shared with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

